As Mission Pharmacal’s president of commercial operations, Terrell Herring oversees strategy and brand positioning for the company. In addition, he focuses on product development and key new hires. Under Terrell Herring’s leadership, Mission Pharmacal also has succeeded in forging profitable new partnerships. At the beginning of 2018, Mission Pharmacal announced that it had established a partnership with Fabre-Kramer Pharmaceuticals, Inc., on a project to manufacture the antidepressant medication Travivo in extended-release tablet form. Travivo (generic name Gepirone HCL) is designed to treat generalized anxiety disorder. The two companies have elected to facilitate the transfer of the Fabre-Kramer technology to Mission for the making of registration batches of Travivo. Travivo’s advantages include its ability to function in the body without causing the types of chemical dependency, amnesia, and sexual dysfunctions that are often among the common side-effects of competing products. After Mission produces the registration batches, executives will submit the associated data to the US Food and Drug Administration as part of the agency’s review and approval process. Following anticipated FDA approval, Mission and Fabre-Kramer will focus on their joint agreement for Mission’s ongoing production of Travivo.
0 Comments
Leave a Reply. |
AuthorTerrell Herring began working at Mission Pharmacal Company in 2010, bringing more than 25 years of experience in the pharmaceutical industry to his role as President of Commercial Operations. Archives
February 2018
Categories
All
|